Clinical Trial Update: MS-275 in Treating Patients With Hematologic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of MS-275 (entinostat) in patients with hematologic cancers, including leukemia, multiple myeloma/plasma cell neoplasms, and myelodysplastic Syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Plasma Cell Neoplasm

Drugs mentioned

• MS-275 (entinostat)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: COMPLETED